Monte Rosa Therapeutics (GLUE) Capital Expenditures (2020 - 2026)

Monte Rosa Therapeutics' Capital Expenditures history runs 7 years deep, the most recent figure standing at $2.7 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 800.0% year-over-year to $2.7 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 510.33% increase from a year earlier, with the FY2025 full-year figure at $149000.0, up 198.0% from the prior year.
• Capital Expenditures rose to $2.7 million in Q1 2026 per GLUE's latest filing, from -$290000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $17.8 million in Q4 2023 and bottomed at -$14.4 million in Q3 2023.
• The 5-year median for Capital Expenditures is $983000.0 (2024), against an average of $2.1 million.
• Across the five-year window, Capital Expenditures soared 4391.03% in 2023 and slumped 812.53% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $8.2 million in 2022, then jumped by 117.76% to $17.8 million in 2023, then plunged by 121.13% to -$3.8 million in 2024, then jumped by 92.28% to -$290000.0 in 2025, then soared by 1043.45% to $2.7 million in 2026.
• Per Business Quant, the three latest GLUE Capital Expenditures figures stand at $2.7 million (Q1 2026), -$290000.0 (Q4 2025), and -$2.8 million (Q3 2025).